Online inquiry

IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14153MR)

This product GTTS-WQ14153MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14153MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3867MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ5855MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ7433MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ3176MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ9665MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ10457MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ10973MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ12947MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW